Language
English
Publication Date
12-1-2024
Journal
Laboratory Investigation
DOI
10.1016/j.labinv.2024.102160
PMID
39426568
PMCID
PMC11709230
PubMedCentral® Posted Date
12-1-2025
PubMedCentral® Full Text Version
Author MSS
Abstract
Precision oncology is driven by biomarkers. For glioblastoma multiforme (GBM), the most common malignant adult primary brain tumor, O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation is an important prognostic and treatment clinical biomarker. Time consuming pre-analytical steps such as biospecimen storage, fixation, sampling, and processing are sources of data irreproducibility, and all these pre-analytical variables are confounded by intratumor heterogeneity of MGMT promoter methylation. To assess the effect of pre-analytical variables on GBM DNA methylation, tissue storage/sampling (CryoGrid), sample preparation multi-sonicator (PIXUL), and 5-methylcytosine (5mC) DNA immunoprecipitation (Matrix MeDIP-qPCR/seq) platforms were used. MGMT promoter methylation status assayed by MeDIP-qPCR was validated with methylation specific PCR (MS-PCR). MGMT promoter methylation levels in frozen and formalin fixed paraffin embedded (FFPE) sample pairs were not statistically different, confirming reliability of FFPEs for MGMT promoter methylation analysis. Warm ex-vivo ischemia (up to 4hrs at 37°C) and 3 cycles of repeated sample thawing and freezing did not statistically impact 5mC at MGMT promoter, exon, and enhancer regions, indicating the resistance of DNA methylation to common variations in sample processing conditions that might be encountered in research and clinical settings. 26–34% of specimens exhibited intratumor heterogeneity in the MGMT DNA promoter methylation. These data demonstrate that variations in sample fixation, ischemia duration and temperature, and DNA methylation assay technique do not have a statistically significant impact on MGMT promoter methylation assessment. However, intratumor methylation heterogeneity underscores the value of multiple biopsies at different GBM geographic tumor sites in the evaluation of MGMT promoter methylation status. Matrix-MeDIP-seq analysis revealed that MGMT promoter methylation status clustered with other differentially methylated genomic loci (e.g. HOXA and lncRNAs) that are resilient to variation in the above pre-analytical conditions. These observations offer new opportunities to develop more granular data-based epigenetic GBM biomarkers. In this regard, the high throughput CryoGrid-PIXUL-Matrix toolbox could be useful.
Keywords
DNA Methylation, Humans, Brain Neoplasms, Promoter Regions, Genetic, DNA Modification Methylases, DNA Repair Enzymes, Tumor Suppressor Proteins, Glioblastoma, Glioma, Specimen Handling, Biomarkers, Tumor, Female, Male, Glioblastoma, DNA methylation, MGMT, pre-analytical variables, FFPE, CryoGrid, PIXUL, Matrix MeDIP-qPCR/seq
Published Open-Access
yes
Recommended Citation
Bomsztyk, Karol; Mar, Daniel; Denisenko, Oleg; et al., "Analysis of DNA Methylation in Gliomas: Assessment of Preanalytical Variables" (2024). Faculty and Staff Publications. 5336.
https://digitalcommons.library.tmc.edu/baylor_docs/5336